Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Paul Rutgeerts(Universitair Ziekenhuis Leuven), Brian G. Feagan(Western University), Gary R. Lichtenstein(Hospital of the University of Pennsylvania), Lloyd Mayer(Mount Sinai Medical Center), Stefan Schreiber(Kiel University), Jean‐Frédéric Colombel(Hôpital Claude Huriez), Daniel Rachmilewitz(Tel Aviv Sourasky Medical Center), Douglas C. Wolf(Atlanta Gastroenterology Associates), Allan Olson, Weihang Bao, Stephen B. Hanauer(University of Chicago Medical Center)
Cited by 947
Abstract
Related Papers
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al.|New England Journal of Medicine|1997|3.2k
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair et al.|New England Journal of Medicine|2000|3k